Acute hepatic porphyrias-A guide for hepatologists
- PMID: 38607698
- DOI: 10.1097/HEP.0000000000000880
Acute hepatic porphyrias-A guide for hepatologists
Abstract
The acute hepatic porphyrias (AHPs) are a group of rare, inherited disorders of the heme biosynthesis pathway, usually manifesting with attacks of acute abdominal pain and other neurovisceral symptoms, with or without cutaneous manifestations. AHPs are characterized by the accumulation of porphyrin precursors, porphobilinogen, and/or aminolevulinic acid, in the blood. The diagnosis is often missed or delayed due to both inadequate testing and the improper use of available laboratory tests. In this review, we describe the various clinical presentations of the 4 AHPs, elucidate the approach to diagnosis, and provide recommendations for immediate and long-term management. We also describe the different complications that can occur with long-standing AHP, including the development of HCC. The AHPs are very treatable conditions, with excellent outcomes if diagnosed and treated early. A high index of suspicion for the presence of these disorders, along with accurate testing and timely treatment, will help reduce the burden of disease and prevent irreversible complications in patients with AHP.
Copyright © 2024 American Association for the Study of Liver Diseases.
Similar articles
-
AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.Gastroenterology. 2023 Mar;164(3):484-491. doi: 10.1053/j.gastro.2022.11.034. Epub 2023 Jan 13. Gastroenterology. 2023. PMID: 36642627 Free PMC article. Review.
-
Case-based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management.Liver Int. 2025 Mar;45(3):e15924. doi: 10.1111/liv.15924. Epub 2024 Apr 15. Liver Int. 2025. PMID: 38618923 Review.
-
Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.Orphanet J Rare Dis. 2022 Apr 7;17(1):160. doi: 10.1186/s13023-022-02314-9. Orphanet J Rare Dis. 2022. PMID: 35392955 Free PMC article. Review.
-
Givosiran for the treatment of acute hepatic porphyria.Expert Rev Clin Pharmacol. 2022 Apr;15(4):383-393. doi: 10.1080/17512433.2022.2075848. Epub 2022 May 11. Expert Rev Clin Pharmacol. 2022. PMID: 35531651 Review.
-
Acute Hepatic Porphyrias: Review and Recent Progress.Hepatol Commun. 2018 Dec 20;3(2):193-206. doi: 10.1002/hep4.1297. eCollection 2019 Feb. Hepatol Commun. 2018. PMID: 30766957 Free PMC article. Review.
References
-
- JD P, KE A. The porphyrias In: MA L, JT P, MA L, eds. The Red Cell and Its Diseases, 1 ed.. McGraw-Hill; 2022:395; chap 31.
-
- Stölzel U, Doss MO, Schuppan D. Clinical guide and update on porphyrias. Gastroenterology. 2019;157:365–81.e4.
-
- Anderson KE. Acute hepatic porphyrias: Current diagnosis & management. Mol Genet Metab. 2019;128:219–27.
-
- Akagi R, Inoue R, Muranaka S, Tahara T, Taketani S, Anderson KE, et al. Dual gene defects involving delta-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient. Br J Haematol. 2006;132:237–43.
-
- Rudd A, Grant J, Varigos G, Morgan V, Winship I. Co-existence of hereditary coproporphyria and porphyria cutanea tarda: The importance of genetic testing. Australas J Dermatol. 2013;54:e50–2.
LinkOut - more resources
Full Text Sources